Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia

Hawk Kim; Kyoo Hyung Lee; Sung Soo Yoon; Sang Kyun Sohn; Young Don Joo; Sung Hyun Kim; Byung Soo Kim; Jung Hye Choi; Jae Youg Kwak; Myung Soo Hyun; Sung Hwa Bae; Ho Jin Shin; Jong Ho Won; Sukjoong Oh; Won Sik Lee; Jae Hoo Park; Chul Won Jung

doi:10.1016/j.bbmt.2012.03.015

Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia

Hawk Kim, Kyoo Hyung Lee, Sung Soo Yoon, Sang Kyun Sohn, Young Don Joo, Sung Hyun Kim, Byung Soo Kim, Jung Hye Choi, Jae Youg Kwak, Myung Soo Hyun, Sung Hwa Bae, Ho Jin Shin, Jong Ho Won, Sukjoong Oh, Won Sik Lee, Jae Hoo Park, Chul Won Jung

Department of Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

Although younger age is associated with favorable prognosis in adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aplastic anemia (AA), other pretransplantation factors may be more important than age. We retrospectively analyzed the impact of older age on transplantation outcomes and survival in a total of 225 adult patients with AA who underwent allo-HSCT: 57 patients >40 years old (older patient group [OPG]) and 168 patients ≤40 years old (younger patient group [YPG]). Age at allo-HSCT ≤40 years, time from diagnosis to allo-HSCT ≤6 months, and matched related donor (MRD) were favorable prognostic factors in all study patients. Risk analysis of survival in the OPG showed that age >50 years was the only poor prognostic factor. Survival did not differ significantly between the YPG and patients <50 years old in the OPG. In conclusion, patients between the ages of 41 and 50 years with severe AA and MRDs should undergo allo-HSCT as early as possible to optimize survival.

Original language	English
Pages (from-to)	1500-1508
Number of pages	9
Journal	Biology of Blood and Marrow Transplantation
Volume	18
Issue number	10
DOIs	https://doi.org/10.1016/j.bbmt.2012.03.015
Publication status	Published - 2012 Oct

Keywords

Allogeneic hematopoietic stem cell transplantation
Aplastic anemia
Elderly

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1016/j.bbmt.2012.03.015

Cite this

Kim, H., Lee, K. H., Yoon, S. S., Sohn, S. K., Joo, Y. D., Kim, S. H., Kim, B. S., Choi, J. H., Kwak, J. Y., Hyun, M. S., Bae, S. H., Shin, H. J., Won, J. H., Oh, S., Lee, W. S., Park, J. H., & Jung, C. W. (2012). Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia. Biology of Blood and Marrow Transplantation, 18(10), 1500-1508. https://doi.org/10.1016/j.bbmt.2012.03.015

Kim, H, Lee, KH, Yoon, SS, Sohn, SK, Joo, YD, Kim, SH, Kim, BS, Choi, JH, Kwak, JY, Hyun, MS, Bae, SH, Shin, HJ, Won, JH, Oh, S, Lee, WS, Park, JH & Jung, CW 2012, 'Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia', Biology of Blood and Marrow Transplantation, vol. 18, no. 10, pp. 1500-1508. https://doi.org/10.1016/j.bbmt.2012.03.015

@article{0c1d7e8a66f443ea853bb87ccd5cb582,

title = "Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia",

abstract = "Although younger age is associated with favorable prognosis in adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aplastic anemia (AA), other pretransplantation factors may be more important than age. We retrospectively analyzed the impact of older age on transplantation outcomes and survival in a total of 225 adult patients with AA who underwent allo-HSCT: 57 patients >40 years old (older patient group [OPG]) and 168 patients ≤40 years old (younger patient group [YPG]). Age at allo-HSCT ≤40 years, time from diagnosis to allo-HSCT ≤6 months, and matched related donor (MRD) were favorable prognostic factors in all study patients. Risk analysis of survival in the OPG showed that age >50 years was the only poor prognostic factor. Survival did not differ significantly between the YPG and patients <50 years old in the OPG. In conclusion, patients between the ages of 41 and 50 years with severe AA and MRDs should undergo allo-HSCT as early as possible to optimize survival.",

keywords = "Allogeneic hematopoietic stem cell transplantation, Aplastic anemia, Elderly",

author = "Hawk Kim and Lee, {Kyoo Hyung} and Yoon, {Sung Soo} and Sohn, {Sang Kyun} and Joo, {Young Don} and Kim, {Sung Hyun} and Kim, {Byung Soo} and Choi, {Jung Hye} and Kwak, {Jae Youg} and Hyun, {Myung Soo} and Bae, {Sung Hwa} and Shin, {Ho Jin} and Won, {Jong Ho} and Sukjoong Oh and Lee, {Won Sik} and Park, {Jae Hoo} and Jung, {Chul Won}",

note = "Funding Information: This work was supported by Priority Research Center Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology ( 2010-0029621 ). ",

year = "2012",

month = oct,

doi = "10.1016/j.bbmt.2012.03.015",

language = "English",

volume = "18",

pages = "1500--1508",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia

AU - Kim, Hawk

AU - Lee, Kyoo Hyung

AU - Yoon, Sung Soo

AU - Sohn, Sang Kyun

AU - Joo, Young Don

AU - Kim, Sung Hyun

AU - Kim, Byung Soo

AU - Choi, Jung Hye

AU - Kwak, Jae Youg

AU - Hyun, Myung Soo

AU - Bae, Sung Hwa

AU - Shin, Ho Jin

AU - Won, Jong Ho

AU - Oh, Sukjoong

AU - Lee, Won Sik

AU - Park, Jae Hoo

AU - Jung, Chul Won

N1 - Funding Information: This work was supported by Priority Research Center Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology ( 2010-0029621 ).

PY - 2012/10

Y1 - 2012/10

N2 - Although younger age is associated with favorable prognosis in adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aplastic anemia (AA), other pretransplantation factors may be more important than age. We retrospectively analyzed the impact of older age on transplantation outcomes and survival in a total of 225 adult patients with AA who underwent allo-HSCT: 57 patients >40 years old (older patient group [OPG]) and 168 patients ≤40 years old (younger patient group [YPG]). Age at allo-HSCT ≤40 years, time from diagnosis to allo-HSCT ≤6 months, and matched related donor (MRD) were favorable prognostic factors in all study patients. Risk analysis of survival in the OPG showed that age >50 years was the only poor prognostic factor. Survival did not differ significantly between the YPG and patients <50 years old in the OPG. In conclusion, patients between the ages of 41 and 50 years with severe AA and MRDs should undergo allo-HSCT as early as possible to optimize survival.

AB - Although younger age is associated with favorable prognosis in adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aplastic anemia (AA), other pretransplantation factors may be more important than age. We retrospectively analyzed the impact of older age on transplantation outcomes and survival in a total of 225 adult patients with AA who underwent allo-HSCT: 57 patients >40 years old (older patient group [OPG]) and 168 patients ≤40 years old (younger patient group [YPG]). Age at allo-HSCT ≤40 years, time from diagnosis to allo-HSCT ≤6 months, and matched related donor (MRD) were favorable prognostic factors in all study patients. Risk analysis of survival in the OPG showed that age >50 years was the only poor prognostic factor. Survival did not differ significantly between the YPG and patients <50 years old in the OPG. In conclusion, patients between the ages of 41 and 50 years with severe AA and MRDs should undergo allo-HSCT as early as possible to optimize survival.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Aplastic anemia

KW - Elderly

UR - http://www.scopus.com/inward/record.url?scp=84866172587&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2012.03.015

DO - 10.1016/j.bbmt.2012.03.015

M3 - Article

C2 - 22472480

AN - SCOPUS:84866172587

SN - 1083-8791

VL - 18

SP - 1500

EP - 1508

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 10

ER -

Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this